Key Fact	Detail
Report	Forensic Short — Closed Case
Publication date	February 15, 2020
Issuer	Insys Therapeutics, Inc. (defunct via Chapter 11)
Ticker	NASDAQ: INSY
Original short	Citron Research — "Insys: The Most Reckless Subsys Marketing" (August 2016)
Headline post-publication events	DOJ investigation; indictment of founder John Kapoor and senior executives (December 2016); racketeering conviction of all five (May 2019); $225M DOJ settlement (June 2019); Insys Chapter 11 (June 10, 2019); Kapoor sentenced to 5.5 years (January 2020)
Rating	SHORT — Closed Case

---

Why We Are Publishing Today

Insys Therapeutics is the modern reference case for opioid-marketing-driven pharmaceutical fraud. Citron Research's August 2016 short — published into an existing wave of skepticism about Insys's Subsys (sublingual-fentanyl) marketing practices — preceded by months a DOJ indictment that ultimately produced the first US pharmaceutical-executive RICO conviction in connection with opioid marketing. The May 2019 convictions of founder John Kapoor and four senior executives, the June 2019 Chapter 11 filing, and Kapoor's January 2020 sentencing form one of the most-complete closed-loop forensic-short outcomes in any sector.

---

Section 1 — The Citron Thesis (August 2016)

Citron Research's report alleged that Insys Therapeutics:

• Marketed its lead product Subsys — a sublingual fentanyl spray approved for the management of breakthrough pain in opioid-tolerant cancer patients — to non-cancer patient populations through aggressive sales practices, including a speaker-program payment structure that effectively functioned as kickbacks to high-prescribing physicians;
• Generated reported revenue trajectories that depended on the continuation of this off-label-promotion model;
• Was facing DOJ and state-attorney-general scrutiny that, if it resulted in enforcement, would substantially compromise the underlying business model.

Citron disclosed a short position. The Citron report followed and built on a substantial body of investigative journalism — particularly by STAT News and others — that had documented the Subsys speaker-program structure.

Section 2 — Federal Indictment and Subsequent Convictions

The post-publication sequence developed across the federal-prosecution timeline:

• December 2016. US Attorney for the District of Massachusetts indicts founder John Kapoor, former CEO Michael Babich, and several senior sales and marketing executives on racketeering, conspiracy, and related charges.
• 2017–2019. Multi-defendant trial; key cooperator testimony from former regional sales executives.
• May 2019. All five trial defendants convicted of racketeering conspiracy under the Racketeer Influenced and Corrupt Organizations Act (RICO).
• June 2019. Insys settles related DOJ civil and criminal allegations against the company for approximately US$225 million, including a guilty plea by a subsidiary.
• January 2020. John Kapoor sentenced to 5.5 years (66 months) in federal prison; co-defendants receive sentences in similar ranges.

Section 3 — Insys Chapter 11 (June 10, 2019)

Following the cumulative weight of the racketeering conviction, civil-litigation liability, and the DOJ settlement obligation, Insys Therapeutics filed for Chapter 11 bankruptcy in the US Bankruptcy Court for the District of Delaware on June 10, 2019. The Chapter 11 proceeding involved sale of company assets and resolution of opioid-related civil claims through the bankruptcy estate. Common equity in Insys was effectively zero in subsequent distributions.

Section 4 — Where Things Stand (February 2020) and What Muddy Insights Takes From The Case

As of February 2020:

• Insys Therapeutics is wound down through the completed Chapter 11.
• The criminal-conviction record stands; sentences have been substantially served.

What Muddy Insights takes from the Insys case:

1. It is the first US pharmaceutical-executive RICO conviction for opioid marketing. The criminal-procedure outcome is, in this respect, a landmark.
2. Speaker-program payment structures warrant heightened scrutiny. Where a pharmaceutical issuer's reported revenue is materially correlated with payments to high-prescribing physicians under speaker-program or similar structures, the Insys template warrants application as a diagnostic.
3. Investigative-journalism + activist-short complementarity is the model. The Insys outcome was the product of multi-year investigative reporting (particularly STAT News) that the Citron report and subsequent short-side commentary synthesized. The cumulative-pressure model — journalists, short-sellers, and federal prosecutors operating in parallel — is, in our view, the modal mechanism by which substantive fraud cases reach closure.

---

Source Index (selected)

• Citron Research, "Insys: The Most Reckless Subsys Marketing," August 2016.
• STAT News investigative reporting on Subsys speaker programs, 2015–2017.
• United States v. Kapoor et al., indictment (December 2016) and trial proceedings, US District Court for the District of Massachusetts; convictions May 2019.
• US Department of Justice — Insys Therapeutics global settlement, approximately US$225 million, June 2019.
• In re Insys Therapeutics, Inc., Chapter 11 proceedings, US Bankruptcy Court for the District of Delaware, commenced June 10, 2019.

---

— Muddy Insights, February 15, 2020.